This week’s announcement that two Chinese children were born with CRISPR-modified genes exploded onto the global stage. Experts joined Good Morning America and took to Twitter, sharing their fears for the future and for the children’s health and discussing their concerns about the ethical quandaries realized sooner than some had expected.
Wall Street, however, was unfazed.
Share prices for three publicly traded companies using CRISPR — Editas (EDIT), Intellia (NTLA) and CRISPR Therapeutics (CRSP) — haven’t faltered. If anything, most CRISPR-based stocks have become more valuable since the announcement. Editas’s and CRISPR Therapeutics’ share prices rose about 15 percent over the course of the week; Intellia’s was up by about 4 percent.